[Safety evaluation of 10 μg recombinant hepatitis B vaccine (saccharomyces cerecisiae yeast) based on the results of a phase of Ⅳ clinical trial]

Zhonghua Yu Fang Yi Xue Za Zhi. 2017 Dec 6;51(12):1121-1123. doi: 10.3760/cma.j.issn.0253-9624.2017.12.014.

[Article in Chinese]

Authors

Y Zeng¹, J K Zhang, Y Tang, Z H Yang, J L Su, L Y Chen, Z H Huang, P Y Zeng, Z Y Jian, W M Du, M W Yang, T T Wang, F Z Wang, X F Liang, H Z Zheng

Affiliation

¹ Shenzhen Kangtai Biological Products CO., LTD., Shenzhen 518057, China.

PMID: 29262496
DOI: 10.3760/cma.j.issn.0253-9624.2017.12.014

No abstract available

Keywords: Adverse reactions; Clinical trial; Hepatitis B vaccines; Infant, newborn.